Novavax | NVAX - Selling And Administration Expenses


Novavax reported $25.53M in Selling and Administration Expenses for its fiscal quarter ending in December of 2025.





Selling And Administration Expenses Change Date
Adma Biologics USD 26.74M 6.55M Mar/2026
Agenus USD 6.21M 4.34M Mar/2026
AstraZeneca USD 5.8B 735M Jun/2026
BioCryst Pharmaceuticals USD 63.98M 31.8M Jun/2026
Cassava Sciences USD 3.89M 2.77M Mar/2026
Geron USD 35.42M 6.24M Mar/2026
GlaxoSmithKline GBP 2.19B 75M Jun/2026
MannKind USD 58.3M 4.22M Jun/2026
Merck USD 2.89B 219M Jun/2026
Minerva Neurosciences USD 2.48M 58.79K Sep/2024
Moderna USD 216M 43M Jun/2026
Novartis USD 3.14B 296M Mar/2026
Novavax USD 25.53M 1.34M Dec/2025
Pfizer USD 3.41B 496M Jun/2026
Sanofi EUR 2.63B 307M Jun/2026
Sarepta Therapeutics USD 107.6M 53.57M Jun/2026
TG Therapeutics USD 62.32M 10.82M Jun/2026